Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Wright Reports
$75.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces FDA Acceptance Of IND For Company’s EGFR-Targeting ADC, IMGN289


Thursday, 1 Aug 2013 04:01pm EDT 

ImmunoGen Inc announced that the Company`s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is active. This enables ImmunoGen to advance IMGN289 into human clinical testing, expected to start in 4Q2013. This is the third IND for a, wholly owned anticancer compound to be submitted by ImmunoGen and accepted by the FDA in the past two years. 

Related Company News

Company Quote

13.99
-0.22 -1.55%
17 Apr 2014